Antidepressant Use During Pregnancy and the Risk of Preterm Delivery and Fetal Growth Restriction
- 1 December 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 29 (6) , 555-560
Abstract
Objective: The associations between prenatal exposure to antidepressants and preterm delivery and fetal growth restriction are controversial and poorly understood. We studied the relation between antidepressant use and these outcomes. Methods: Analysis included women with nonmalformed infants interviewed in the Slone Epidemiology Center Birth Defects Study between 1998 and 2008. We estimated odds ratios (ORs) and 95% confidence intervals (CIs) for premature and small-for-gestational age (SGA) offsprings, adjusting for sociodemographic, lifestyle, medical, and reproductive factors. Results: The frequencies of preterm delivery were 7.3% among the 5710 nonusers (reference), 8.9% among the 192 selective serotonin reuptake inhibitor (SSRI) users (OR, 1.1; 95% CI, 0.6-2.0), and 15.3% among the 59 non-SSRI antidepressant users (OR, 2.2; 95% CI, 1.0-4.9); the respective frequencies of delivering an SGA offspring were 7.2%, 10.9% (OR, 1.7; 95% CI, 1.0-2.7), and 13.6% (OR, 2.2; 95% CI, 1.0-4.9). Compared with nonusers, the frequencies of preterm delivery (7.6%) and SGA offspring (5.7%) were not increased among the 106 women who discontinued SSRIs before the end of the first trimester. Among women who continued SSRIs beyond the first trimester, 10.5% delivered a preterm infant (OR, 1.3; 95% CI, 0.6-2.8) and 17.4% had an SGA offspring (OR, 3.0; 95% CI, 1.7-5.5). Conclusions: Women treated with SSRIs late in pregnancy had a higher frequency of delivering SGA infants, and women receiving non-SSRI antidepressants were more likely to deliver premature and SGA offsprings. The findings suggest an effect of underlying mood disorder or an effect common to both drug classes. In any case, prenatal antidepressant use may help identify women at elevated risks of delivering preterm and SGA infants.Keywords
This publication has 39 references indexed in Scilit:
- Selective Serotonin Reuptake Inhibitor Use and Risk of Gestational HypertensionAmerican Journal of Psychiatry, 2009
- Maternal use of selective serotonin re‐uptake inhibitors and persistent pulmonary hypertension of the newbornPharmacoepidemiology and Drug Safety, 2008
- Delivery Outcome in Relation to Maternal Use of Some Recently Introduced AntidepressantsJournal of Clinical Psychopharmacology, 2007
- Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancyPharmacoepidemiology and Drug Safety, 2007
- Increasing use of antidepressants in pregnancyAmerican Journal of Obstetrics and Gynecology, 2007
- Prenatal Depression, Prenatal Anxiety, and Spontaneous Preterm Birth: A Prospective Cohort Study Among Women With Early and Regular CarePsychosomatic Medicine, 2006
- Selective Serotonin-Reuptake Inhibitors and Persistent Pulmonary Hypertension of the NewbornNew England Journal of Medicine, 2006
- The association between pregnancy processes, preterm delivery, low birth weight, and postpartum depressions—The need for interdisciplinary integrationAmerican Journal of Obstetrics and Gynecology, 2005
- The impact of depression and fluoxetine treatment on obstetrical outcomeArchives of Women's Mental Health, 2004
- Prevalence of Depression During Pregnancy: Systematic ReviewObstetrics & Gynecology, 2004